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Abstract 
Treatment resistance, relapse and metastasis remain critical issues in some challenging 
cancers, such as chondrosarcomas. Boron-neutron Capture Therapy (BNCT) is a targeted 
radiation therapy modality that relies on the ability of boron atoms to capture low energy 
neutrons, yielding high linear energy transfer alpha particles. We have developed an innovative 
boron-delivery system for BNCT, composed of multifunctional fluorescent mesoporous silica 
nanoparticles (B-MSNs), grafted with an activatable cell penetrating peptide (ACPP) for 
improved penetration in tumors and with Gadolinium for magnetic resonance imaging (MRI) 
in vivo. Chondrosarcoma cells were exposed in vitro to an epithermal neutron beam after B-
MSNs administration. BNCT beam exposure successfully induced DNA damage and cell death, 
including in radio-resistant ALDH+ cancer stem cells (CSCs), suggesting that BNCT using 
this system might be a suitable treatment modality for chondrosarcoma or other hard-to-treat 
cancers.  
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Remarkable progress has been made in the understanding and treatment of human cancer, 
resulting in a greatly improved survival rate for many patients. However, such achievements 
remain incomplete or out of reach for some hard-to-treat cancers, such as pancreatic cancer, 
glioblastoma or bone tumors. Chondrosarcomas are cartilaginous tumors which represent the 
second most common primary bone tumor in adults [1]. Chondrosarcomas are notoriously 
resistant to conventional radiation therapy and to chemotherapy, and complete surgical 
resection remains to this day the primary treatment. A number of patients experience relapse, 
metastasis or present unresectable disease with poor clinical outcome [2].  
Tumors are heterogeneous and are comprised of cells with various morphological and 
molecular features, including a subset of tumor-initiating dedifferentiated cells with self-
renewing abilities. These cancer stem cells (CSCs) are capable of reconstituting tumor 
heterogeneity, and a large amount of evidence strongly suggests that they may contribute to 
treatment resistance, relapse and metastasis [3]. CSCs have been identified in a number of 
tumors, including chondrosarcomas [4]. Several features of CSCs have been reported to explain 
their intrinsic radioresistance: lower levels of basal and radiation-induced reactive oxygen 
species (ROS), improved DNA damage repair activation and apoptosis inhibition or relative 
quiescent state [5]. New approaches are thus highly expected to address treatment-resistant 
tumors, which may include targeting CSCs. 
In addition to conventional X-ray therapy, new high linear linear energy transfer (LET) 
radiation therapy modalities have emerged which might finally contribute overcoming 
treatment resistance, such as boron neutron capture therapy (BNCT) or carbon-ion particle 
therapy [6]. High LET therapies, alone or combined with other targeted treatments (like the 
PARP inhibitor talazoparib or the chemotherapeutic drug cisplatin), may be able to overcome 
 
CSC-related resistance [6–11]. BNCT is an innovative experimental treatment modality that 
relies on the ability of 10B to capture thermal neutrons, resulting in the release of high-linear 
energy transfer (LET) α (4He) particles and lithium (7Li) nuclei, with a path length shorter than 
10 µm [12]. Therefore, it is crucial to maximize the concentration of boron-enriched 
compounds in tumor tissues while minimizing levels in surrounding normal tissues. 
Furthermore, intracellular boron delivery should be achieved, due to the short path length of α 
(4He) particles. Because BNCT releases high-LET radiation, it should provide improved 
relative biological effectiveness (RBE) and a lower oxygen enhancement ratio (OER), 
compared to conventional X-ray therapy. BNCT clinical trials have been performed on patients 
suffering from head and neck, brain, lung and liver cancers [12], with some encouraging results 
in terms of overall survival, recurrence and metastasis. For those reasons, BNCT might also be 
an effective strategy for the treatment of radioresistant tumors, such as clear cell sarcoma (CSS) 
[13], osteosarcoma [14] or chondrosarcoma.  
Even though the first BNCT trials have been performed more than half a century ago, BNCT 
has not yet become an established treatment modality, due to two main limiting factors [15]. 




boronophenylalanine (L-10BPA). Reported tumor-to-normal tissue (T/N) ratio for BSH does 
not always reach 1. New advances are necessary to improve T/N ratio with low toxicity. Second, 
the sole neutron sources traditionally available for BNCT were nuclear reactors. Recent 
advances in nanotechnologies for drug delivery and the development of new accelerator-based 
neutron sources promise to overcome those limitations.  Here, we report a new theranostic 
multi-functional boron-delivery system based on mesoporous silica nanoparticles (B-MSNs). 
We tested this system using an accelerator-based neutron beam for BNCT. 
 
Nanoparticles (NPs) have recently emerged as a promising therapeutic tool for a variety of 
medical applications. NPs allow the encapsulation of therapeutic compounds with higher 
protection against metabolic degradation and the ability to control and target drug release 
preferentially in tumor tissues [16]. The accumulation of NPs in tumor tissues has been 
attributed to the poor alignment of neovascularization and lymphatic drainage in those areas, 
so called enhanced permeability (EPR) effect [17]. In particular, much attention has been 
devoted to the design of MSNs, which present a number of advantageous features: tunable size 
(usually 50 to 200 nm diameter), easy surface functionalization, large mesopore volume for 
efficient drug loading, in vitro and in vivo tolerance [18,19]. They might therefore serve as 
ideal boron-delivery agents for BNCT.  
Methods 
Synthesis of mesoporous silica nanoparticles.  
Synthesis steps are represented in Scheme S1. 
- Synthesis of fluorescent MCM-41 (1) 
FITC (5.5 mg) was dissolved in 3 mL of ethanol under argon, then APTES (12 µL) was 
added and the reaction was stirred for 2 hours at room temperature. In a separate flask, CTAB 
(0.5 g) was dissolved in a mixture of MilliQ water (240 mL) and NaOH 2M (1.75 mL), and the 
mixture was stirred at 80°C. After 2 hours, the FITC-APTES solution was slowly added to the 
CTAB solution and the reaction was carried out at 80°C. After 2 hours, the reactional mixture 
was allowed to cool down to room temperature and the precipitate was filtrated with a fritted 
glass (porosity 3) and thoroughly washed with methanol. The powder was crushed and dried 
overnight under high vacuum. 
- Grafting of APTES on nanoparticle surface (2) 
 
Nanoparticles obtained during step 1 - NP(1) - were suspended in methanol (50 mL) for 5 
minutes, then APTES (3 mL) was added and the mixture was stirred overnight at room 
temperature. The suspension was centrifuged and washed three times with methanol, then 
allowed to dry for 2 hours under high vacuum.  
- Surfactant removal (3) 
NP(2) were dispersed in a mixture of HCl (5 mL) and methanol (90 mL) and stirred at reflux 
for 24 hours. The suspension was centrifuged and washed with methanol, then allowed to dry 
for 2 hours under high vacuum. 
- Ammonium neutralization and aggregates elimination (4) 
NP(3) were dispersed in DMSO (50 mL) then piperidine (12.5 mL) was added to neutralize 
ammonium. The mixture was bath sonicated for 40 minutes at room temperature, then 
centrifuged at 500 g for 10 minutes to eliminate aggregates. Nanoparticles were centrifuged 
and washed twice with DMSO and twice with methanol. The nanoparticles were dried under 
high vacuum for 2 hours. 
- Grafting of MeO-PEG-COO-NHS (5 kDa) and Mal-PEG-COO-NHS (10 kDa) (5) 
NP(4) were dispersed in DMSO (50 mL), then Mal-PEG-NHS 10 kDa (5 mg) was added to 
the nanoparticles and stirred for 30 minutes. Next, MeO-PEG-NHS 5 kDa (95 mg) was added 
to the nanoparticle suspension. The mixture was stirred over night at room temperature, then 
centrifuged and washed three times with methanol. The nanoparticles were dried overnight 
under high vacuum. 
- Grafting of APTES inside pores (6) 
 
NP(5) were dispersed in methanol (50 mL) for 15 minutes in sonication bath, then APTES 
(3 mL) was slowly added. The mixture was stirred for 24 hours at room temperature then the 
suspension was centrifuged and the nanoparticles are washed three times with methanol. The 
nanoparticles were dried overnight under high vacuum. 
- Grafting of HOOC-CH2-Br inside the pores (7) 
NP(6) were dispersed in DMSO for 15 minutes in sonication bath, then N,N'-
Dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) were added to the 
nanoparticle suspension. Finally, HOOC-CH2-Br was added and the mixture was left reacting 
over night at room temperature. The nanoparticles were centrifuged and washed three times 
with methanol. The nanoparticles were dried under high vacuum for 2 hours. 
- Incorporation of BSH inside pores (8) 
NP(7) were dispersed in a mixture of ACN/H2O (50 mL in proportion 4/1) under argon, then 
10B-enriched Sodium mercaptoundecahydro-dodecaborate (Na2[
10B12H11SH]) (Stella Chemifa, 
Osaka, Japan) (250 mg) and TCEP were added (300 mg). The reaction was stirred under argon 
overnight at room temperature. The suspension was centrifuged, and the nanoparticles are 
washed three times with methanol. The nanoparticles were dried under high vacuum for 2 hours. 
m = 290 mg 
- Grafting of Activatable cell penetrating peptide (9) 
NP(8) were dispersed in PBS (15 mL) adjusted to pH 7.0 with HCl. In a separate flask, 
Activatable cell penetrating peptide (ACPP) (1 mg) and tris(2-carboxyethyl)phosphine (TCEP) 
(6.6 mg, 100 equivalents) were dissolved in PBS pH 7.0. The pH was adjusted from 3.5-4.0 to 
7.0 with 1M NaOH. Argon was bubbled in the nanoparticle suspension maintained in a 
sonication bath for one hour, and the peptide solution was bubbled with argon for 1 h. Then, 
 
the peptide solution was slowly added to the nanoparticle suspension and stirred for one 
additional hour at room temperature under argon. The mixture was centrifuged and washed 
twice successively with PBS, water and DMSO. Then, the nanoparticles were suspended in 
DMSO (30 mL) and bath sonicated for 1 hour at room temperature, in order to disaggregate 
the nanoparticles. Aggregates were removed by centrifugating the nanoparticles at 500 g for 
10 min, then the nanoparticles were centrifugated at 30,000 g for 30 min and washed 3 times 
with methanol. The nanoparticles were dried overnight under vacuum. 
Synthesis of nanoparticles for MRI experiments 
The nanoparticles used for MRI experiments were synthesized by using a modified protocol. 
The 6 first steps are similar to the synthesis described above. The following steps were done 
as described below.  
- Grafting of Gd-DTPA inside the pores (7) 
 300 mg of NP(7) were dispersed in DMSO for 15 minutes in sonication bath, then Gd-
DTPA (547 mg, 1 mmol), N,N'-Dicyclohexylcarbodiimide (DCC, 825 mg, 4 mmol) and N-
hydroxysuccinimide (NHS, 460 mg, 4 mmol) were added to the nanoparticle suspension. The 
mixture was stirred at room temperature for 48 hours. The nanoparticles were centrifuged and 
washed three times with methanol. The nanoparticles were dried under high vacuum for 2 hours. 
m = 254 mg. 
- Grafting of Activatable cell penetrating peptide (8) 
200 mg of NP(7) were dispersed in PBS (15 mL) adjusted to pH 7.0 with HCl. In a separate 
flask, Activatable cell penetrating peptide (ACPP) (1 mg) and tris(2-carboxyethyl)phosphine 
(TCEP) (6.6 mg, 100 equivalents) were dissolved in PBS pH 7.0. The pH was adjusted from 
3.5-4.0 to 7.0 with 1M NaOH. Argon was bubbled in the nanoparticle suspension maintained 
 
in a sonication bath for one hour, and the peptide solution was bubbled with argon for 1 h. 
Then, the peptide solution was slowly added to the nanoparticle suspension and stirred for one 
additional hour at room temperature under argon. The mixture was centrifuged and washed 
twice successively with PBS, water and DMSO. Then, the nanoparticles were suspended in 
DMSO (30 mL) and bath sonicated for 1 hour at room temperature, in order to disaggregate 
the nanoparticles. Aggregates were removed by centrifugating the nanoparticles at 500 g for 
10 min, then the nanoparticles were centrifugated at 30,000 g for 30 min and washed 3 times 
with methanol. The nanoparticles were dried overnight under vacuum. m = 78 mg. 
DLS and zeta-potential. Nanoparticles suspensions in milliQ water (100 µg/mL) were 
analyzed on a Zetasizer Nano ZS instrument (Malvern Instruments, Malvern, UK). 
Hydrodynamic radius and zeta-potential were analyzed by Dynamic Light Scattering (DLS) 
and Laser Doppler Velocimetry (LDV), respectively. 
Synthesis of Activatable Cell Penetrating Peptide (ACPP). Reagents and solvents, which 
were used as received, were purchased from Wako Pure Chemical Industries (Osaka, Japan), 
Sigma-Aldrich (St. Louis, MO), Watanabe Chemical Industries (Hiroshima, Japan), and Tokyo 
Chemical Industries (Tokyo, Japan). Activatable Cell Penetrating Peptide (ACPP) Ac-
E8PLGLAGR8N-Acp-C-NH2 was synthesized using the Fmoc (9-
fluorenylmethyloxycarbonyl) / tBu (tert-Butyl) based solid-phase method. Standard protected 
Fmoc-amino acids (0.141 mmol) or Fmoc--Acp-OH (N-(9-fluorenylmethyloxycarbonyl)-6-
aminohexanoic acid) were sequentially coupled to a Fmoc-NH-SAL Resin (100 mg, 0.047 
mmol) using the DIPCI (0.141 mmol)-HOBt (0.141 mmol) method. Coupling steps were 
performed for 2 h in DMF (1.0 mL) after removal of each Fmoc group with 20% piperidine-
DMF (1.5 mL, 5+15 min) to obtain resin-bound protected peptide. N-terminal acylation was 
carried out by reacting the peptide resin at r.t. with acetic anhydride (Ac2O) / N,N-
 
diisopropylethylamine (DIPEA) (50 eq + 50 eq) in DMF for 1 hour. Cleavage from the resins 
and removal of side chain protecting groups were achieved by treatment with TFA-m-cresol-
thioanisole-EDT (4.0 mL, 40:1:1:1 v:v:v:v) for 3 h at room temperature, followed by 
preparative reversed phase (RP)-HPLC purification in a 0.1% aqueous TFA-CH3CN system to 
obtain the desired ACPP as TFA salts. The purity of synthesized ACPP was > 95% in RP-
HPLC analysis using a SunFire C18 reverse-phase column (4.6 x 150 mm, 5μm) (Waters, 
Milford, MA, USA) with a binary solvent system: a linear gradient of CH3CN (10-30%, 40 
min) in 0.1% aqueous TFA at a flow rate of 1.0 mL/min, detected at UV 230 nm. Yields of 
ACPP obtained as a white powder were calculated as TFA salts. High-resolution mass 
spectrometry (HR-MS) (TOF MS ES+) was recorded on a Micromass LCT (Waters).  Results 
were: Yield: 51.3% (42 mg); HRMS m/z [M+H]+ found : 3179.6292 (calculated for 
C127H219N51O43S: 3179.6317); HPLC purity: 96% (tR = 17.79 min) (Figure S2). 
Inductively coupled plasma mass spectrometry (ICP-MS). B-MSNs were dissolved at a 
concentration of 1 mg/mL in 1M Potassium hydroxide (KOH), then kept in an ultrasound bath 
for 24 hours. Then MilliQ H2O and 5% of Nitric acid (HNO3) 67% were added. Determination 
of boron content in the samples was performed using an Element 2 ICP-MS system (Thermo 
Scientific, Waltham, MA, USA). No glass container or glass equipment were used for ICP-MS 
experiments, to avoid sample contamination. 
Transmission electron microscopy (TEM). Nanoparticles were suspended at a 
concentration of 0.2-1.0 mg/mL in water, and 20 µL were deposited on a copper grid covered 
by carbon film. After 30 seconds, the drop was removed with paper tissue and the grid was air 
dried for 1 hour. Observation of nanoparticles was performed under a JEM1230R electron 
microscope (JEOL) at the energy of 100 keV. Nanoparticles element composition was analyzed 
on a JEM-ARM200F electron microscope (JEOL) using energy-dispersive x-ray spectroscopy 
 
(EDS) and electron energy-loss spectroscopy (EELS). For in vitro visualization of 
nanoparticles cell penetration, CH-2879 chondrosarcoma cells were treated with nanoparticles, 
then were prepared according to standard protocols as recommend by the electron microscope 
manufacturer (JEOL). Briefly, cells were fixed with 2.5% glutaraldehyde in PBS, then post-
fixation was performed using 1% osmium tetroxide (OsO4) in PBS. Fixed cells were 
dehydrated using increasing concentrations of ethanol (from 50% to 100%). Substitution was 
performed using various mixes of propylene oxide (PO) and epoxy resin. Cells were then 
embedded in TAAB EPON 812 epoxy resin, placed in a silicon embedding plate and resin was 
polymerized at 60ºC for one day. 70 nm sections were placed on a TEM grid and observed on 
a JEM1230R electron microscope (JEOL). 
Mouse experiments. 4-week old BALB/c nu/nu male mice (Japan SLC, Hamamatsu, Japan) 
were maintained on a 12-hr light/12-hr dark cycle in a temperature-controlled (22°C) barrier 
facility with free access to water and a normal diet (CLEA Japan, Tokyo, Japan). Mice were 
allowed to acclimatize for 5 days before the experiment. 106 CH-2879 chondrosarcoma cells 
mixed 1:1 with Matrigel Growth Factor Reduced (Corning, Corning, NY, USA) were injected 
subcutaneously into mouse flank. Tumor volumes were measured using calipers. Mice were 
used for MRI experiments when tumor volume reached at least 500 mm3. Mouse experiment 
protocols were approved by the Animal Care and Use Committee at Okinawa Institute of 
Science and Technology Graduate University. 
Magnetic resonance imaging (MRI). Gadolinium-nanoparticles diluted in sterile PBS were 
injected into the tail vein of tumor-bearing mice. Mice were scanned at regular intervals under 
isoflurane anesthesia using an 11.7-T Bruker MRI (Bruker Biospec GmbH, Ettlingen, 
Germany). T1 maps were carried out using rapid acquisition with relaxation enhancement 
(RARE) with TE= 6 ms, variable TR= 200, 531, 958, 1557, 2568, 7500 ms, flip angle (FA)= 
 
90-degree, number of averages (NA)= 1. T2 maps were carried out using multiple- spin echo 
with 60 TEs from 6 to 179 ms, TR= 2200 ms, FA= 90-degree, NA= 1. Imaging planes were 
coronal slices with FOV= 38 × 28 mm, matrix size= 256 × 96, and slice thickness= 2 mm for 
both T1 and T2 maps. 
Cell culture and sorting of cancer stem cells. CH-2879 chondrosarcoma cells [20] and T/C 
28AT immortalized chondrocytes [21] were grown in RPMI1640 and DMEM media, 
respectively (Nacalai, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) 
(Cosmo Bio, Tokyo, Japan) and antibiotic-antimycotic solution (Penicillin, Streptomycin, 
Amphotericin B. Gibco ThermoFisher, Carlsbad, CA, USA). Cultures were grown in 5% CO2 
at 95% humidity. As previously [22], ALDH activity in the cells was measured by flow 
cytometry using the ALDEFLUOR kit (Stemcell technologies, Vancouver, BC, Canada). Cells 
with low and high levels of ALDH enzymatic activity (respectively ALDH- and ALDH+ cells) 
were sorted using a FACSAria cell sorter (BD Biosciences, Franklin Lakes, NJ, USA). As a 
negative control, cells were treated with diethylaminobenzaldehyde (DEAB), a specific ALDH 
inhibitor. 
Western blotting. CH-8279 cells were lysed with radioimmunoprecipitation assay (RIPA) 
buffer (Santa Cruz Biotechnology, Dallas, TX, USA). Protein concentrations were determined 
using the Protein Assay CBB solution (Nacalai) using bovine serum albumin (BSA) as a 
standard. 20 µg protein were loaded on Any kD Mini-PROTEAN TGX precast gel (Bio-Rad, 
Hercules, CA, USA). After separation, the proteins were transferred onto a PVDF Membrane 
(Bio-Rad). Membranes were probed with anti-MMP2 (Cell Signaling Technology, Danvers, 
MA, USA) and anti--tubulin (MBL, Woburn, MA, USA) antibodies. Staining was detected 
using an HRP-conjugated anti-rabbit secondary antibody and Chemi-Lumi One L assay kit 
(Nacalai) on a ImageQuant LAS 4000 imager (GE Healthcare, Chicago, IL, USA). 
 
Evaluation of nanoparticles cytotoxicity. In vitro viability was measured by trypan blue 
exclusion, using a TC10 automated cell counter (Bio-Rad). To evaluate in vivo toxicity, 
nanoparticles were injected in the tail vein of healthy mice and body weight was measured for 
several weeks.  
Radiation exposure. X-ray experiments were performed using an M-150WE X-ray 
generator (Softex, Tokyo, Japan) at 140 kVp, 8 mA, 80V. Irradiation dose-rate was 1.3 Gy/min. 
BNCT biological irradiation experiments were performed at the accelerator-based BNCT 
facility of the Ibaraki Neutron Medical Research Center (Tokai, Japan) [23]. Neutron beam 
characteristics for each experimental run are summarized in Table S1. 100 µL/mL 
nanoparticles were administrated 3 hours before irradiation. Shortly before exposure to neutron 
beam, plated cells were trypsinized and transferred to 0.5 mL microtubes. After irradiation, 
cells were either processed for immediate analysis or replated for next day analysis, depending 
on the endpoint.  
Flow cytometry analysis of apoptosis and DNA damage. Collected samples were analyzed 
on a Muse flow cytometer (Millipore Sigma, Burlington, MA, USA), using the Muse 
Multicaspase Assay Kit and the Muse Multicolor DNA damage Kit, according to 
manufacturer’s instructions.  
Clonogenic assay. After irradiation, CH-2879 cells and CSCs were seeded in 6-well plates 
at defined densities, incubated for 10–14 days then stained as previously described[7]. Colonies 
with >50 cells were scored and surviving fractions were determined after correcting for the 
plating efficiency.  
Statistical analysis. Clonogenic survival curve data were fitted to the linear-quadratic model 
(for X-ray irradiations) or linear model (for BNCT), using the CS-Cal software 
(www.oncoexpress.de). Statistical significance of the difference between dose-response curves 
 
was performed using one-way Analysis of Variance (one-way ANOVA) with Bonferroni 
correction for pairwise group comparisons, with SigmaPlot software 
(systatsoftware.com/products/sigmaplot/). Other significant differences were assessed using 
Student’s t-test (p<0.05). 
Results 
We have developed multifunctional MSNs, which can serve as boron-delivery carrier and 
can be monitored for BNCT dosimetry (Figure 1, Scheme S1). The mean diameter of inorganic 
core, as determined by transmission electronic microscopy (TEM), was around 100 nm (Figure 
1b), within the range generally accepted for achieving optimal therapeutic effect [24]: 
nanoparticles smaller than 10 nm in diameter encounter renal clearance, while bigger 
nanoparticles may not be able to penetrate and diffuse into the tumor. In order to improve 
biocompatibility and blood circulation time [25], a layer of polyethylene glycol (PEG, 5kDa 
95w%, 10 kDa 5 w%) was grafted onto the surface of nanoparticles by peptide bond (Figure 
2a). It is usually considered that grafting of PEG with molecular weight of at least 2 kDa is 
necessary to avoid clearing by the mononuclear phagocyte system [26]. PEG also allowed 
steric stabilization of the nanoparticles, which did not form significant aggregates in culture 
media [27]. After PEG grafting, the hydrodynamic radius of B-MSNs, measured by dynamic 
light scattering (DLS), was around 200 nm (Figure 2b).  
The nanoparticles didn’t show any significant toxicity in vitro (Figure S3) or in vivo 
(Figure S4) and exhibited good stability and dispersion properties, as confirmed by analysis of 
zeta potential values (consistently lower than -25 mV) and the measurement of bovine serum 
albumin (BSA) absorption (Figure S5). Extended stability and dispersion properties were 
reported for similar MSNs [28]. MSNs are considered to be biocompatible, as toxicity can be 
observed only for high particle concentrations [29]. 
 
Sufficient amounts of 10B (about 20 μg/g weight or about 109 atoms/cell) need to be 
delivered to tumor cells for the success of BNCT [30]. Furthermore, because the track of  
particles generated by boron-neutron capture is 10 µm at most, it is necessary that a sufficient 
proportion of 10B penetrate inside cells for optimal efficiency. Large amounts of boron might 
be loaded into nanoparticle mesopores as o-carborane [31], however there is a risk of carborane 
leakage and unpredictable boron distribution. Here, we propose to attach 10B-enriched BSH 
inside mesopores, using an aminosilane coupling agent. Inductively coupled plasma mass 
spectrometry (ICP-MS) measurements confirmed the successful accumulation of 10B on B-
MSNs, which contain 1.27% mass fraction of boron (95% 10B), representing around 5 x 1017 
atoms of 10B per mg nanoparticles (Table 1). Subsequent steps of nanoparticle synthesis did 
not lead to release of BSH. This suggests that if in vivo B-MSN delivery to tumors could be 
optimized, the amount of boron reaching tumor cells might be sufficient for BNCT treatment. 
In order to efficiently enter cells by endocytosis, nanoparticles are commonly surface-
modified with cell penetrating peptides (CPPs). Surface functionalization of the nanoparticles 
with an activatable cell penetrating peptide (ACPP) allows for efficient tumor targeting. Our 
ACPP consists of three regions (Figure 3a): a polyanionic autoinhibitory domain (octaglutamic 
acid E8), a PLGLAG linker region (sensitive to proteases) and a cell-penetrating polycationic 
domain (octaarginine R8) [32,33]. In addition, an Acp (aminohexanoic acid) moiety is grafted 
on the C-terminal portion of the peptide to serve as a spacer between the polycationic domain 
and the Cys residue for a better efficiency in the thiol-maleimide coupling strategy used. In the 
intact ACPP, the polyanionic peptide domain prevents uptake of the polycationic domain. 
Matrix metalloproteinases (MMP) 2 and 9 (generally overexpressed in tumors [34]) cleave the 
PLGLAG linker, releasing the cell-penetrating R8 portion grafted on the nanoparticle. Indeed, 
chondrosarcoma cells expressed higher levels of MMP-2 than normal chondrocytes (Figure 
 
3b), leading to enhanced relative cellular uptake, compared to nanoparticles grafted only with 
polyethylene glycol (PEG) (Figures 3c and 3d).  
Unlike other radiation therapy modalities (X-rays or charged particle beams), calibration 
and dosimetry for BNCT relies on many parameters, including neutron beam properties and 
boron uptake in tumors. In this context, it is crucial to properly monitor the biodistribution of 
boron-delivery compounds, if possible in a non-invasive way. Although our B-MSNs include 
Fluorescein isothiocyanate (FITC), allowing fluorescent tracking for in vitro and small animal 
studies, the depth limitation of optical imaging methods seriously hampers their clinical utility. 
We have therefore also developed MSNs grafted with Gadolinium for in vivo visualization 
using magnetic resonance imaging (MRI) [35,36]. These nanoparticles were injected into the 
tail vein of nude mice bearing xenograft chondrosarcoma tumors. Longitudinal (T1) and 
transverse (T2) relaxation times were measured for 24h in the tumor (Figures 4, S6). Due to its 
paramagnetic properties, gadolinium shortens T1 and T2 when it accumulates. While T1 values 
did not change significantly after injection, we observed a clear decrease in T2 values, reflecting 
nanoparticles tumor uptake. T2 shortening effects of gadolinium are usually observed at high 
enough concentration [37,38]. Relative lack of T1-weighted contrast is expected at high 
magnetic fields (11.7 T), as reported previously [39]. Accordingly, increased loading of 
gadolinium on nanoparticles led to changes in T2, but not T1 values (Figure S6). Better overall 
T1-weighted contrast may be expected at lower fields in MRI systems for routine clinical use. 
Still, our results suggest that MRI might be a suitable technique for nanoparticle biodistribution 
and BNCT dose assessments after optimization. 
In order to verify the efficiency of our boron-delivery system in vitro, CH-2879 
chondrosarcoma cells [20] and an ALDH+ radioresistant CSC subpopulation (around 1%) [40] 
(Figure 5a) were exposed to an epithermal neutron beam at the iBNCT facility [23] (Table S1). 
Although apoptosis induction after 24h was limited (Figure 5c), BNCT beam exposure resulted 
 
in significant DNA damage levels and lower clonogenic survival (Figure 5be). BNCT exposure 
of cells in the absence of B-MSNs did not trigger DNA damage, suggesting that the biological 
effects of the neutron beam resulted from BNCT reaction. Comparison of survival curves may 
allow for a rough estimation of RBEs for dosimetry in this experimental system. Doses 
resulting in 10% survival (D10) were 5.86 Gy for X-rays and 0.42 mA.h (about 6.7x10
11 n/cm2) 
for neutron beam.  
Interestingly, while CSCs were more resistant to conventional X-ray therapy than the 
general CH-2879 cell population (Figure 5d), no significant difference was observed in cells 
exposed to neutron beam (Figure 5e), suggesting that high-LET radiation exposures such as 
BNCT might be more efficient at targeting CSCs than other treatment modalities, as observed 
for carbon-ion therapy [7]. 
Discussion 
The short range of alpha particles generated during the 10B(n,α,γ)7Li nuclear reaction of 
BNCT provides the theorical ability to selectively target tumors cells. This could make BNCT 
an attractive treatment modality if improvements in boron-delivery and monitoring could be 
achieved [12]. Only two FDA-approved boron delivery compounds are currently adopted for 
clinical use: BPA and BSH [41,42]. However, those two compounds lack specificity and do 
not allow the near-simultaneous measurement of boron biodistribution offered by theranostic 
delivery systems. 
Our multi-functional B-MSNs may be a suitable delivery system for BNCT in some 
resistant cancers. Other boron-delivery strategies have included the encapsulation of boron-
curcumin in poly(lactic-co-glycolic acid) (PLGA) nanoparticles [43], the use of boron cluster-
containing polyion complex (PIC) nanoparticles [44], a boron-rich MAC-TAC liposomal 
system [45], the delivery of dipeptides of BPA and Tyrosine by cancer-upregulated peptide 
 
transporters 1 and 2 (PEPT1, PEPT2) [46], or the use of radiolabelled fluoroboronotyrosine 
(FBY) for Positron Emission Tomography (PET)-guided BNCT [47]. Our B-MSNs exhibit 
several advantageous features when compared with other organic and inorganic drug delivery 
systems: well-described synthesis steps and applications, easily tuneable particle and pore size, 
high flexibility for further functionalization, suitability for theranostic approaches [48]. 
Furthermore, B-MSNs design and properties may be tailored based on tumor characteristics 
[49]. 
Ultimately, clinical dose estimation for BNCT will require both the determination of 
neutron beam dose components and of boron uptake and biodistribution. Tsukuba-plan, a 
treatment planning system (TPS) for BNCT has been developed, which employs the Particle 
and Heavy Ion Transport code System (PHITS) as a Monte Carlo transport code [50,51]. 
Personalized dosimetry might also be possible by performing real-time detection (using Single 
Photon Emission Computed Tomography - SPECT) of the gamma-rays emitted by excited 7Li 
as a result of BNCT reactions [52]. The visualization of boron tumor uptake requires the 
functionalization of boron-delivery systems with a suitable molecular imaging reporter, like 
18F for PET or Fe/Gd for MRI, while optical imaging may be suitable only for small animal 
studies. Although PET is usually more sensitive, it requires the use of radioactive tracers, 
whereas MRI provides high spatial resolution; both techniques are considered sufficiently 
sensitive for clinical BNCT applications [53]. For example, hepatocytes could be visualized by 
MRI when cells integrated at least  4 x 107 Gd complexes per cell [54].  
Overcoming treatment resistance might require an effective targeting of radioresistant 
CSCs [55,56]. Therapeutic strategies against CSCs have included inhibition of WNT and 
NOTCH pathways, ablation using antibody-drug conjugates (ADCs) or epigenetic therapy, 
each with potential drawbacks or limitations [57]. High-LET radiation treatment, in 
combination with other targeted therapies, has shown favorable results in bypassing tumor and 
 
CSC radioresistance. Using our boron-delivery system, BNCT might be capable of efficiently 
targeting radioresistant CSCs in hard-to-treat tumors, such as chondrosarcoma. The ability of 
nanoparticle-based systems to target specific or diffuse tumor sites, as observed in malignant 
mesothelioma [58], is also of particular interest for BNCT. The combination of different boron-
delivery approaches may also improve tumor boron targeting and treatment efficacy [59]. 
Recently, a number of proton accelerator-based neutron sources have been commissioned for 
research and clinical use [60], opening new perspectives for the potential development of 
BNCT as a viable new cancer therapy modality.   
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Figure legends 
Figure 1. Synthesis of Boron-delivery mesoporous silica nanoparticles (B-MSNs). (a) 
Mesoporous silica MCM-41 fluorescent nanoparticles were PEGylated, then BSH (B10-
enriched) was incorporated. Finally, an activatable cell penetrating peptide (ACPP) was grafted. 
(b) Visualization of B-MSNs by transmission electronic microscopy (TEM). (c) Energy-
dispersive X-ray spectroscopy. Peaks for Boron (BKa), Oxygen (OKa) and Silicon (SiKA) are 
identified in green. 
Figure 2. Characterization of Boron-delivery mesoporous silica nanoparticles (B-MSNs). 
(a) NMR quantification of PEG grafted on MSNs at various synthesis steps. (b) Measurement 
of the hydrodynamic radius of B-MSNs by dynamic light scattering (DLS). 
Figure 3. Cellular uptake of functionalized boron-delivery nanoparticles (B-MSNs). (a) 
Matrix metalloproteinase (MMP)-mediated cleavage of the linker PLGLAG region releases the 
polycationic octaarginine (R8) region of the activatable cell penetrating peptide (ACPP). (b) 
Chondrosarcoma cells express more MMP-2 protein than normal chondrocytes. (c) B-MSN 
cellular uptake is improved in chondrosarcoma cells, as measured by flow cytometry three 
hours after MSN administration. (d) B-MSNs functionalized with ACPP penetrate cells by 
endocytosis, as observed by transmission electronic microscopy (TEM). 
Figure 4. Time-course of T1 and T2 values in xenograft chondrosarcoma tumors before 
and after intravenous nanoparticle injection. (a) Average T1 values in the tumor, normalized 
to phantom. (b) Average T2 values in the tumor, normalized to phantom. 
Figure 5. Boron-neutron capture therapy (BNCT) of chondrosarcoma cells with boron-
delivery nanoparticles. (a) Sorting of chondrosarcoma ALDH+ cancer stem cells. DEAB-
treated cells served as negative control. (b) BNCT induces DNA damage. ATM and H2AX 
phosphorylation levels were measured in non-irradiated and irradiated CH-2879 cells, 
respectively. (c) BNCT induces limited apoptosis 24h after irradiation. (d-e) CSCs are 
 
comparatively resistant to X-rays (d), but not to BNCT (e), compared with non-CSC CH-2879 
cells, as observed after performing clonogenic assays. Neutron beam exposures were 
performed on cells after administration of mesoporous silica nanoparticles (MSNs) 
functionalized with activatable cell-penetrating peptide (ACPP). 
Table legends 
Table 1. Quantification of Boron content by ICP-MS. Measurements were performed 
after BSH incorporation and after grafting of ACPP. 
